ArticleFrontiers in oncology2026

Plasma multi-omics reveals molecular remodeling and prognostic biomarkers in advanced breast cancer treated with trastuzumab deruxtecan.

Die Sang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.